172 related articles for article (PubMed ID: 37520682)
1. Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.
Osum SH; Oribamise EI; Corbière SMAS; Taisto M; Jubenville T; Coutts A; Kirstein MN; Fisher J; Moertel C; Du M; Bedwell D; Largaespada DA; Watson AL
Mol Ther Nucleic Acids; 2023 Sep; 33():227-239. PubMed ID: 37520682
[TBL] [Abstract][Full Text] [Related]
2. Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I.
Li K; Turner AN; Chen M; Brosius SN; Schoeb TR; Messiaen LM; Bedwell DM; Zinn KR; Anastasaki C; Gutmann DH; Korf BR; Kesterson RA
Dis Model Mech; 2016 Jul; 9(7):759-67. PubMed ID: 27482814
[TBL] [Abstract][Full Text] [Related]
3. Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations.
McHugh DR; Cotton CU; Hodges CA
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396210
[TBL] [Abstract][Full Text] [Related]
4. Functional restoration of mouse Nf1 nonsense alleles in differentiated cultured neurons.
Wu C; Iyer S; Wolfe SA; Jacobson A
J Hum Genet; 2022 Nov; 67(11):661-668. PubMed ID: 35945271
[TBL] [Abstract][Full Text] [Related]
5. Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases.
Keeling KM
Diseases; 2016 Dec; 4(4):. PubMed ID: 28367323
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression.
Keeling KM; Wang D; Dai Y; Murugesan S; Chenna B; Clark J; Belakhov V; Kandasamy J; Velu SE; Baasov T; Bedwell DM
PLoS One; 2013; 8(4):e60478. PubMed ID: 23593225
[TBL] [Abstract][Full Text] [Related]
7. Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.
Osum SH; Coutts AW; Duerre DJ; Tschida BR; Kirstein MN; Fisher J; Bell WR; Delpuech O; Smith PD; Widemann BC; Moertel CL; Largaespada DA; Watson AL
Neurooncol Adv; 2021; 3(1):vdab020. PubMed ID: 33978635
[TBL] [Abstract][Full Text] [Related]
8. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
Williams KB; Largaespada DA
Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
[TBL] [Abstract][Full Text] [Related]
9. NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.
Pros E; Larriba S; López E; Ravella A; Gili ML; Kruyer H; Valls J; Serra E; Lázaro C
Hum Mutat; 2006 Nov; 27(11):1104-14. PubMed ID: 16937374
[TBL] [Abstract][Full Text] [Related]
10. Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes.
Adachi H; Pan Y; He X; Chen JL; Klein B; Platenburg G; Morais P; Boutz P; Yu YT
Mol Cell; 2023 Feb; 83(4):637-651.e9. PubMed ID: 36764303
[TBL] [Abstract][Full Text] [Related]
11. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
Bidou L; Bugaud O; Belakhov V; Baasov T; Namy O
RNA Biol; 2017 Mar; 14(3):378-388. PubMed ID: 28145797
[TBL] [Abstract][Full Text] [Related]
12. Regulation of neurofibromin expression in rat sciatic nerve and cultured Schwann cells.
Wrabetz L; Feltri ML; Kim H; Daston M; Kamholz J; Scherer SS; Ratner N
Glia; 1995 Sep; 15(1):22-32. PubMed ID: 8847098
[TBL] [Abstract][Full Text] [Related]
13. Therapeutics based on stop codon readthrough.
Keeling KM; Xue X; Gunn G; Bedwell DM
Annu Rev Genomics Hum Genet; 2014; 15():371-94. PubMed ID: 24773318
[TBL] [Abstract][Full Text] [Related]
14. Recoding of Nonsense Mutation as a Pharmacological Strategy.
Temaj G; Telkoparan-Akillilar P; Nuhii N; Chichiarelli S; Saha S; Saso L
Biomedicines; 2023 Feb; 11(3):. PubMed ID: 36979640
[TBL] [Abstract][Full Text] [Related]
15. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
[TBL] [Abstract][Full Text] [Related]
16. Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs.
Ko W; Porter JJ; Sipple MT; Edwards KM; Lueck JD
Mol Ther Nucleic Acids; 2022 Jun; 28():685-701. PubMed ID: 35664697
[TBL] [Abstract][Full Text] [Related]
17. Caffeine boosts Ataluren's readthrough activity.
Lentini L; Melfi R; Cancemi P; Pibiri I; Di Leonardo A
Heliyon; 2019 Jun; 5(6):e01963. PubMed ID: 31294114
[TBL] [Abstract][Full Text] [Related]
18. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
19. Downstream Alternate Start Site Allows N-Terminal Nonsense Variants to Escape NMD and Results in Functional Recovery by Readthrough and Modulator Combination.
Bowling A; Eastman A; Merlo C; Lin G; West N; Patel S; Cutting G; Sharma N
J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143233
[TBL] [Abstract][Full Text] [Related]
20. Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner.
Alewine G; Knight J; Ghantae A; Mamrega C; Attiah B; Coover RA; Fahrenholtz CD
J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
